Literature DB >> 12519780

Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression.

Gudrun Urban1, Teresa Golden, Ileana V Aragon, Lex Cowsert, Scott R Cooper, Nicholas M Dean, Richard E Honkanen.   

Abstract

Serine/threonine phosphatase 5 (PP5) can act as a suppresser of p53-dependent growth suppression and has been reported to associate with several proteins, including the glucocorticoid receptor/heat-shock protein-90 complex. Still, the physiological/pathological roles of PP5 are unclear. To characterize the relationship of PP5, glucocorticoid receptor activation and p53, here we describe the development of chimeric antisense oligonucleotides that potently inhibit human p53 expression. This allowed us to regulate the expression of either p53 (e.g. with ISIS 110332) or PP5 (e.g. with ISIS 15534) in genetically identical cells. Studies with ISIS 110332 revealed that the suppression of p53 expression is associated with a decrease in the basal expression of the cyclin-dependent kinase inhibitor protein, p21(WAF1/Cip1), and a concomitant increase in the rate of cell proliferation. Suppression of p53 also blocks dexamethasone-induced p21(WAF1/Cip1) expression and G(1)-growth arrest. Furthermore, treatment with ISIS 110332, but not the mismatched controls, ablates the suppression of growth produced by prior treatment with dexamethasone. Additional studies revealed that dexamethasone-dependent p21(WAF1/Cip1) expression occurs without an apparent change in p53 protein levels or the phosphorylation status of p53 at Ser-6, -37, or -392. However, dexamethasone treatment is associated with an increase in p53 phosphorylation at Ser-15. Suppression of PP5 expression with ISIS 15534 also results in the hyperphosphorylation of p53 at Ser-15. Together, these findings indicate that the basal expression of p53 plays a functional role in a glucocorticoid receptor-mediated response regulating the expression of p21(Waf1/Cip1) via a mechanism that is suppressed by PP5 and associated with the phosphorylation of p53 at Ser-15.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519780     DOI: 10.1074/jbc.M210993200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Posttranslational regulation of the mammalian circadian clock by cryptochrome and protein phosphatase 5.

Authors:  Carrie L Partch; Katherine F Shields; Carol L Thompson; Christopher P Selby; Aziz Sancar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-21       Impact factor: 11.205

Review 2.  Targeting protein serine/threonine phosphatases for drug development.

Authors:  Jamie L McConnell; Brian E Wadzinski
Journal:  Mol Pharmacol       Date:  2009-03-19       Impact factor: 4.436

3.  Knockdown of protein phosphatase 5 inhibits ovarian cancer growth in vitro.

Authors:  Xiaojiao Zheng; Lianxiao Zhang; Bohong Jin; Fubin Zhang; Duoyi Zhang; Lining Cui
Journal:  Oncol Lett       Date:  2015-10-26       Impact factor: 2.967

4.  Molecular basis for TPR domain-mediated regulation of protein phosphatase 5.

Authors:  Jing Yang; S Mark Roe; Matthew J Cliff; Mark A Williams; John E Ladbury; Patricia T W Cohen; David Barford
Journal:  EMBO J       Date:  2004-12-02       Impact factor: 11.598

5.  Human protein phosphatase 5 dissociates from heat-shock proteins and is proteolytically activated in response to arachidonic acid and the microtubule-depolymerizing drug nocodazole.

Authors:  Tamás Zeke; Nick Morrice; Cristina Vázquez-Martin; Patricia T W Cohen
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

6.  Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.

Authors:  Teresa Golden; Ileana V Aragon; Beth Rutland; J Allan Tucker; Lalita A Shevde; Rajeev S Samant; Guofei Zhou; Lauren Amable; Danalea Skarra; Richard E Honkanen
Journal:  Biochim Biophys Acta       Date:  2008-01-26

7.  The promoter for intestinal cell kinase is head-to-head with F-Box 9 and contains functional sites for TCF7L2 and FOXA factors.

Authors:  Thomas W Sturgill; Paul B Stoddard; Steven M Cohn; Marty W Mayo
Journal:  Mol Cancer       Date:  2010-05-11       Impact factor: 27.401

8.  Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Authors:  Benjamin Theobald; Kathy Bonness; Alla Musiyenko; Joel F Andrews; Gudrun Urban; Xizhong Huang; Nicholas M Dean; Richard E Honkanen
Journal:  Mol Cancer Res       Date:  2013-05-13       Impact factor: 5.852

9.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Authors:  L Gu; N Zhu; H W Findley; M Zhou
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

10.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.